[
  {
    "ts": null,
    "headline": "Moderna, Inc. (MRNA) 7th Annual Evercore ISI HealthCONx Conference - (Transcript)",
    "summary": "Moderna, Inc. (NASDAQ:MRNA) 7th Annual Evercore ISI HealthCONx Conference Call December 4, 2024 1:20 PM ETCompany ParticipantsLavina Talukdar - Senior Vice...",
    "url": "https://finnhub.io/api/news?id=2fe5d043f39cd6855dd26f13e458eaa0f176371ae44cd104170253c229be3b11",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733345324,
      "headline": "Moderna, Inc. (MRNA) 7th Annual Evercore ISI HealthCONx Conference - (Transcript)",
      "id": 131772141,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna, Inc. (NASDAQ:MRNA) 7th Annual Evercore ISI HealthCONx Conference Call December 4, 2024 1:20 PM ETCompany ParticipantsLavina Talukdar - Senior Vice...",
      "url": "https://finnhub.io/api/news?id=2fe5d043f39cd6855dd26f13e458eaa0f176371ae44cd104170253c229be3b11"
    }
  },
  {
    "ts": null,
    "headline": "Moderna CEO says he'll work with Trump using 'facts and data'",
    "summary": "Moderna (MRNA) CEO Stéphane Bancel said that he plans to address any partisan hurdles with the incoming Trump administration’s vaccine and pandemic preparedness policies with “facts and data.”",
    "url": "https://finnhub.io/api/news?id=94c81dd8452603d84fddb7f19d6a52c14fb9f0b9e783c14b9cc22a426697cf38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733342251,
      "headline": "Moderna CEO says he'll work with Trump using 'facts and data'",
      "id": 131772892,
      "image": "https://media.zenfs.com/en/quartz.com/ada281731da01ca90234d84567845586",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) CEO Stéphane Bancel said that he plans to address any partisan hurdles with the incoming Trump administration’s vaccine and pandemic preparedness policies with “facts and data.”",
      "url": "https://finnhub.io/api/news?id=94c81dd8452603d84fddb7f19d6a52c14fb9f0b9e783c14b9cc22a426697cf38"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Moderna Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=79aa18cb46e03a0eff6b6955f37d104b0157743dd515e3520ee911aa9e2b871f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733329920,
      "headline": "Moderna Inc. stock underperforms Wednesday when compared to competitors",
      "id": 131891658,
      "image": "",
      "related": "MRNA",
      "source": "MarketWatch",
      "summary": "Moderna Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=79aa18cb46e03a0eff6b6955f37d104b0157743dd515e3520ee911aa9e2b871f"
    }
  },
  {
    "ts": null,
    "headline": "Biggest Winners And Losers Since The Election",
    "summary": "Of the 13 biggest stock winners, most of them were already big winners leading up to the election, and all but four are currently up over 40% YTD. Click to read.",
    "url": "https://finnhub.io/api/news?id=64126587924f9a8c60dd097e8e1b156e59cfb68846ca2161c0ead7d600937545",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733320380,
      "headline": "Biggest Winners And Losers Since The Election",
      "id": 131768503,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/682739958/image_682739958.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Of the 13 biggest stock winners, most of them were already big winners leading up to the election, and all but four are currently up over 40% YTD. Click to read.",
      "url": "https://finnhub.io/api/news?id=64126587924f9a8c60dd097e8e1b156e59cfb68846ca2161c0ead7d600937545"
    }
  },
  {
    "ts": null,
    "headline": "Hong Kong residents reticent to get latest Covid-19 jab, Moderna survey finds",
    "summary": "Hong Kong residents' willingness in taking the latest Covid-19 vaccine is lower than in Singapore, but higher compared with other Asian markets, according to a new survey by US pharmaceutical giant Moderna, which called on vulnerable groups to get inoculated. Moderna found 52 per cent of Hong Kong respondents said they were willing to get the updated vaccine when it becomes available, while 58 per cent of those surveyed in Singapore were inclined to take the latest jab, according to the findings",
    "url": "https://finnhub.io/api/news?id=13613fe4f945658796a9f84a0856c41d952ab5999d1d9f5408919e7daabe325c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733304600,
      "headline": "Hong Kong residents reticent to get latest Covid-19 jab, Moderna survey finds",
      "id": 131772893,
      "image": "https://s.yimg.com/ny/api/res/1.2/9Nn90daFgSczhhStxkMCEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05NjA-/https://media.zenfs.com/en/south_china_morning_post_us_228/0549221f0cdc3a04c3b55b31d7318f16",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Hong Kong residents' willingness in taking the latest Covid-19 vaccine is lower than in Singapore, but higher compared with other Asian markets, according to a new survey by US pharmaceutical giant Moderna, which called on vulnerable groups to get inoculated. Moderna found 52 per cent of Hong Kong respondents said they were willing to get the updated vaccine when it becomes available, while 58 per cent of those surveyed in Singapore were inclined to take the latest jab, according to the findings",
      "url": "https://finnhub.io/api/news?id=13613fe4f945658796a9f84a0856c41d952ab5999d1d9f5408919e7daabe325c"
    }
  },
  {
    "ts": null,
    "headline": "Roivant Sciences: A Biotech Growth Play With Major Ambitions",
    "summary": "Roivant Sciences' diversified late-stage pipeline and robust financials promise significant growth potential. Read why I maintain my buy rating on ROIV stock.",
    "url": "https://finnhub.io/api/news?id=8551a75b4ebb977d420ef710d4ea926ee9217ede87b46cb8875f82f7e9775a1e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733301000,
      "headline": "Roivant Sciences: A Biotech Growth Play With Major Ambitions",
      "id": 131766090,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1150479205/image_1150479205.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Roivant Sciences' diversified late-stage pipeline and robust financials promise significant growth potential. Read why I maintain my buy rating on ROIV stock.",
      "url": "https://finnhub.io/api/news?id=8551a75b4ebb977d420ef710d4ea926ee9217ede87b46cb8875f82f7e9775a1e"
    }
  }
]